Country: United States
Language: English
Source: NLM (National Library of Medicine)
SEVELAMER HYDROCHLORIDE (UNII: GLS2PGI8QG) (SEVELAMER - UNII:941N5DUU5C)
Genzyme Corporation
SEVELAMER HYDROCHLORIDE
SEVELAMER HYDROCHLORIDE 400 mg
ORAL
PRESCRIPTION DRUG
Renagel ® is indicated for the control of serum phosphorus in patients with chronic kidney disease (CKD) on dialysis. The safety and efficacy of Renagel in CKD patients who are not on dialysis have not been studied. Renagel is contraindicated in patients with bowel obstruction. Renagel is contraindicated in patients with known hypersensitivity to sevelamer hydrochloride or to any of the excipients. Risk Summary Sevelamer hydrochloride is not absorbed systemically following oral administration and maternal use is not expected to result in fetal exposure to the drug. Clinical Considerations Sevelamer hydrochloride may decrease serum levels of fat-soluble vitamins and folic acid in pregnant women [see Clinical Pharmacology (12.2)] . Consider supplementing with these vitamins. Data Animal data In pregnant rats given dietary doses of 0.5, 1.5, or 4.5 g/kg/day of Renagel during organogenesis, reduced or irregular ossification of fetal bones, probably due to a reduced absorption of fat-soluble vit
Renagel ® (sevelamer hydrochloride) tablets are supplied as white, oval, film-coated, compressed tablets, imprinted with RENAGEL 800 containing 800 mg of sevelamer hydrochloride. Renagel 800 mg Tablets are packaged in bottles of 180 tablets. 1 Bottle of 180 ct 800 mg Tablets (NDC 58468-0021-1) Storage: Store at 25°C (77°F): excursions permitted to 15°C–30°C (59°F–86°F). Do not use Renagel after the expiration date on the bottle. [See USP controlled room temperature] Protect from moisture.
New Drug Application
RENAGEL- SEVELAMER HYDROCHLORIDE TABLET, FILM COATED GENZYME CORPORATION ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE RENAGEL SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR RENAGEL. RENAGEL (SEVELAMER HYDROCHLORIDE) TABLETS, FOR ORAL USE INITIAL U.S. APPROVAL: 2000 INDICATIONS AND USAGE Renagel is a phosphate binder indicated for the control of serum phosphorus in patients with chronic kidney disease on dialysis. ( 1) DOSAGE AND ADMINISTRATION Starting dose is one or two 800 mg tablets three times per day with meals. ( 2) Adjust by one tablet per meal in two-week intervals as needed to obtain serum phosphorus target (3.5 to 5.5 mg/dL). ( 2) DOSAGE FORMS AND STRENGTHS Tablets: 800 mg ( 3) CONTRAINDICATIONS Bowel obstruction. ( 4) Known hypersensitivity to sevelamer hydrochloride or to any of the excipients. ( 4) WARNINGS AND PRECAUTIONS Serious cases of dysphagia, bowel obstruction, bleeding gastrointestinal ulcers, colitis, ulceration, necrosis, and perforation have been associated with sevelamer use, some requiring hospitalization and surgery. ( 5.1) ADVERSE REACTIONS The most common reasons for discontinuing treatment were gastrointestinal adverse reactions. ( 6.1) In a parallel design study of 12 weeks duration, treatment-emergent adverse reactions to Renagel tablets in peritoneal dialysis patients included dyspepsia (12%), peritonitis (8%), diarrhea (5%), nausea (5%), constipation (4%), pruritus (4%), abdominal distension (3%), vomiting (3%), fatigue (3%), anorexia (3%), and arthralgia (3%). ( 6.1) Cases of fecal impaction and, less commonly, ileus, bowel obstruction, and bowel perforation have been reported. ( 6.2) TO REPORT SUSPECTED ADVERSE REACTIONS, CONTACT GENZYME CORPORATION AT 1-800-847- 0069 AND OR FDA AT 1-800-FDA-1088 OR WWW.FDA.GOV/MEDWATCH. DRUG INTERACTIONS When clinically significant drug interactions are expected, separate the timing of administration and monitor clinical responses or blood levels of the concom Read the complete document